CN115721445A - A tectorial membrane support for acute cerebral apoplexy vascular intervention treatment - Google Patents
A tectorial membrane support for acute cerebral apoplexy vascular intervention treatment Download PDFInfo
- Publication number
- CN115721445A CN115721445A CN202211588277.1A CN202211588277A CN115721445A CN 115721445 A CN115721445 A CN 115721445A CN 202211588277 A CN202211588277 A CN 202211588277A CN 115721445 A CN115721445 A CN 115721445A
- Authority
- CN
- China
- Prior art keywords
- stent
- membrane
- blood vessel
- wall
- stent graft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention provides a covered stent for vascular interventional therapy of acute stroke, which is characterized by comprising a stent body and a stent membrane, wherein the stent body is provided with a stent core; the stent membrane is attached to the stent body; after the covered stent is placed into a blood vessel, at least one part of the outer surface of the stent membrane is attached to a focus part of the inner wall of the blood vessel; the inner surface of the stent membrane is an ultra-smooth surface, and the resistance of the ultra-smooth surface to blood flow is smaller than that of the inner wall of a normal blood vessel; the outer surface of the stent membrane is provided with a soluble microneedle which contains a medicinal component, so that after the covered stent is placed into a blood vessel, the soluble microneedle releases the medicinal component to a focus part of the inner wall of the blood vessel. The stent has the advantages that the stent film with the super-smooth surface is attached to the narrow part of the inner wall of the blood vessel, so that the thrombosis is prevented, and the blood flow power is improved; the soluble micro-needle releases medicinal components to the focus part of the inner wall of the blood vessel to play a role in treatment.
Description
Technical Field
The invention relates to the field of vascular interventional surgical instruments, in particular to a covered stent for vascular interventional therapy of acute stroke.
Background
Intravascular treatment has become one of the standard treatments for acute stroke due to large vessel occlusion. The intravascular treatment of patients with large-area cerebral infarction has better functional prognosis than the single drug treatment. Two main methods of mechanical removal of thrombi include: (1) a retrievable support; and (2) sucking the catheter.
However, acute intracranial atherosclerosis-associated macrovascular occlusion (ICAS-LVO) is generally not effectively addressed by mechanical embolectomy. Of the ICAS-LVO patients, 84.3% required special rescue treatment including balloon angioplasty, stenting, and infusion of the intraarterial glycoprotein IIb/IIIa inhibitor.
Emergency angioplasty or stenting is a safe, practical, and effective treatment for ICAS-LVO. But has problems that: after treatment, the artery is easy to be re-occluded by re-thrombosis. The reason is that: (1) The stent thrombus removal causes intimal injury, and the function of endothelial cells is damaged to easily cause platelet aggregation; (2) In situ stenotic and sclerosing plaques cannot be eradicated completely, and residual plaques still affect the hemodynamics.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a covered stent for acute cerebral apoplexy vascular interventional therapy, which is characterized by comprising a stent body and a stent membrane; the stent membrane is attached to the stent body; after the covered stent is placed into a blood vessel, at least one part of the outer surface of the stent membrane is attached to a focus part of the inner wall of the blood vessel; the inner surface of the stent membrane is a super-slip surface, and the resistance of the super-slip surface to blood flow is smaller than that of the inner wall of a normal blood vessel; the outer surface of the stent membrane is provided with a soluble microneedle which contains a medicinal component, so that after the covered stent is placed into a blood vessel, the soluble microneedle releases the medicinal component to a focus part of the inner wall of the blood vessel.
Further, the stent body and/or the stent membrane are made of materials which can be degraded and absorbed by the human body.
Furthermore, the inner surface of the support membrane is a bionic super-smooth surface.
Further, the bionic super-slip surface is specifically as follows: the surging liquid film surface based on the nepenthes effect is a smooth and stable solid-liquid composite film layer obtained by pouring a lubricating liquid into a micro-nano porous structure. Or the bionic super-slip surface specifically comprises the following components: a superhydrophobic surface based on the lotus leaf effect.
Further, the covered stent is placed in the blood vessel in a mode of balloon dilatation; or the covered stent is a self-expanding stent.
The covered stent for intravascular intervention has the beneficial effects that the stent body provides radial supporting force, so that a stent membrane is tightly attached to a narrow part of a blood vessel to prevent falling off; the stent membrane with the super-smooth surface is attached to the narrow part of the inner wall of the blood vessel, so that thrombosis is prevented, and the blood flow power is improved; the soluble micro-needle releases medicinal components to the focus part of the inner wall of the blood vessel to play a role in treatment.
Drawings
Other features, objects and advantages of the invention will become more apparent upon reading of the detailed description of non-limiting embodiments with reference to the following drawings:
FIG. 1 is a schematic view of a stent graft provided by the present invention;
fig. 2 is a schematic view of microneedle technology releasing drugs.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the concept of the invention. All falling within the scope of the invention.
Intravascular treatment has become one of the standard treatments for acute stroke due to large vessel occlusion. Intravascular treatment of patients with large-area cerebral infarction has a better functional prognosis than simple drug treatment. Two main methods of mechanical removal of thrombi include: (1) a retrievable support; and (2) sucking the catheter. However, acute intracranial atherosclerosis-associated macrovascular occlusion (ICAS-LVO) is often not effectively addressed by mechanical embolectomy. Of the ICAS-LVO patients, 84.3% required special rescue treatment including balloon angioplasty, stenting, and infusion of the intraarterial glycoprotein IIb/IIIa inhibitor. Emergency angioplasty or stenting is a safe, practical, and effective treatment for ICAS-LVO. The problems with the existing stent implantation techniques are: the arteries are susceptible to reocclusion after treatment. The reason is that: (1) The stent thrombus removal causes intimal injury, and the function of endothelial cells is damaged to easily cause platelet aggregation; (2) In situ stenotic sclerotic plaques cannot be eradicated completely, and residual plaques still affect hemodynamics.
The invention provides a covered stent for vascular interventional therapy of acute stroke, which comprises a stent body and a stent membrane, wherein the stent body is provided with a stent core; the stent membrane is attached to the stent body; the inner surface of the stent membrane is an ultra-smooth surface, so that after the covered stent is placed in a blood vessel, the outer surface of the stent membrane is attached to a focus part of the inner wall of the blood vessel, and the resistance of the inner surface of the stent membrane to blood flow is smaller than that of the inner wall of a normal blood vessel. The stent has the advantages that the stent body provides radial supporting force, so that the stent membrane is tightly attached to the narrow part of the blood vessel to prevent falling off; the stent membrane with the super-smooth surface is attached to the narrow part of the inner wall of the blood vessel, so that the thrombosis is prevented, and the blood flow power is improved.
Further, the stent body and/or the stent membrane are made of materials which can be degraded and absorbed by the human body. The degradable stent is made of high molecular polymer materials and can be decomposed and absorbed by a human body within a certain time. Compared with the traditional stent, the stent has the greatest advantages of degradability, no loss of elasticity of blood vessels and maintenance of the dilating and contracting functions of the blood vessels.
Furthermore, the inner surface of the support membrane is a bionic super-smooth surface. Specifically, the bionic super-slip surface specifically comprises: the surging liquid film surface based on the nepenthes effect is a smooth and stable solid-liquid composite film layer obtained by pouring a lubricating liquid into a micro-nano porous structure. Or the bionic super-slip surface specifically comprises the following components: a superhydrophobic surface based on the lotus leaf effect.
The bionic super-smooth surface mainly comprises a super-hydrophobic surface based on a lotus leaf effect and a super-smooth liquid film surface based on a pitcher plant effect, the surface morphology and wettability can be accurately regulated and controlled along with the development of bionics and micro-nano manufacturing technology, related researches and application thereof are further expanded and extended, and other types of bionic super-smooth surfaces can be obtained. The stent membrane with the inner wall being a bionic super-smooth surface is attached to the narrow part of the inner wall of the blood vessel, so that the flowing blood is not adhered to the stent membrane, the platelet aggregation is prevented, the thrombosis is prevented, and the blood flow power is improved.
Further, as shown in fig. 1 and 2, the outer surface of the stent membrane is provided with soluble microneedles containing pharmaceutical components, so that after the covered stent is placed in a blood vessel, the outer surface of the stent membrane is attached to a focus part of the inner wall of the blood vessel, the soluble microneedles on the outer surface release the pharmaceutical components to the focus part of the inner wall of the blood vessel, and the pharmaceutical components have a therapeutic effect on the focus part or a function of preventing thrombus from being formed again.
The soluble micro-needle drug delivery technology is characterized in that macromolecular drugs or active ingredients are made into micron-sized needle-shaped forms, and a large number of fine drug transmission channels are established in the process of pasting and contacting with the inner wall of a blood vessel, so that the drugs pass through the barrier of the inner wall of the blood vessel, and the permeation and absorption of the drugs are realized.
Further, the covered stent is placed in the blood vessel in a balloon dilatation mode; or the covered stent is a self-expanding stent.
The foregoing description has described specific embodiments of the present invention. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes or modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention. The above-described preferred features may be used in any combination without conflict with each other.
Claims (7)
1. A tectorial membrane stent for acute cerebral apoplexy vascular interventional therapy is characterized by comprising a stent body and a stent membrane; the stent membrane is attached to the stent body; after the covered stent is placed into a blood vessel, at least one part of the outer surface of the stent membrane is attached to a focus part of the inner wall of the blood vessel;
the inner surface of the stent membrane is an ultra-smooth surface, and the resistance of the ultra-smooth surface to blood flow is smaller than that of the inner wall of a normal blood vessel;
the outer surface of the stent membrane is provided with a soluble microneedle, and the soluble microneedle contains pharmaceutical ingredients, so that the soluble microneedle releases the pharmaceutical ingredients to a focus part of the inner wall of a blood vessel after the covered stent is placed into the blood vessel.
2. The stent graft as recited in claim 1, wherein the stent body and/or the stent membrane are made of a material that is degradable and absorbable by the human body.
3. The stent graft as recited in claim 1, wherein the inner surface of the stent membrane is a biomimetic super-slip surface.
4. The stent graft of claim 3, wherein the biomimetic superior-slip surface is in particular: the surging liquid film surface based on the nepenthes effect is a smooth and stable solid-liquid composite film layer obtained by pouring a lubricating liquid into a micro-nano porous structure.
5. The stent graft of claim 3, wherein the biomimetic superior-slip surface is specifically: a superhydrophobic surface based on the lotus leaf effect.
6. The stent graft of claim 1, wherein the stent graft is placed in the vessel by balloon-expandable placement.
7. The stent graft of claim 1, wherein the stent graft is a self-expanding stent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211588277.1A CN115721445A (en) | 2022-12-12 | 2022-12-12 | A tectorial membrane support for acute cerebral apoplexy vascular intervention treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211588277.1A CN115721445A (en) | 2022-12-12 | 2022-12-12 | A tectorial membrane support for acute cerebral apoplexy vascular intervention treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115721445A true CN115721445A (en) | 2023-03-03 |
Family
ID=85301069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211588277.1A Pending CN115721445A (en) | 2022-12-12 | 2022-12-12 | A tectorial membrane support for acute cerebral apoplexy vascular intervention treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115721445A (en) |
-
2022
- 2022-12-12 CN CN202211588277.1A patent/CN115721445A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050049691A1 (en) | Polymeric reconstrainable, repositionable, detachable, percutaneous endovascular stentgraft | |
| WO2015070814A1 (en) | Drug-eluting balloon and preparation method therefor | |
| US20100261662A1 (en) | Utilization of mural thrombus for local drug delivery into vascular tissue | |
| WO2008071047A1 (en) | Nanoporous drug release structure for drug elute instruments and the preparation method thereof | |
| US20070288084A1 (en) | Implantable Stent with Degradable Portions | |
| US10398806B2 (en) | Triple balloon occlusion and infusion catheter for forming a stent in situ | |
| US9226838B2 (en) | Absorbable blood vessel stent | |
| JP2006500996A (en) | Apparatus and method for delivering mitomycin via an eluting biocompatible implantable medical device | |
| JP2010264275A (en) | Coated medical device | |
| US20090155337A1 (en) | Method and agent for in-situ stabilization of vascular tissue | |
| JP2008517662A (en) | Biocompatible and blood compatible polymer compositions | |
| CN209790103U (en) | Drug release device for blood vessel saccule and saccule support | |
| JP2013526946A (en) | Endoprosthesis coating with polymer fiber tight mesh coating | |
| US20090105811A1 (en) | Intravascular Devices for Cell-Based Therapies | |
| Yoon et al. | Stent technology in ischemic stroke | |
| CN113018660A (en) | Microneedle balloon for interventional drug delivery | |
| CN112370638A (en) | Medicine balloon | |
| CN110548212A (en) | Double-balloon catheter with self-perfusion function | |
| ES2376405T3 (en) | MEDICAL DEVICES FOR LOCALIZED MEDICINAL ADMINISTRATION. | |
| US20120283624A1 (en) | Drug Eluting Device and Method of Use Thereof | |
| CN115721445A (en) | A tectorial membrane support for acute cerebral apoplexy vascular intervention treatment | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| US20080311086A1 (en) | Use of Keratinocyte Composition for the Treatment of Restenosis | |
| US20190308000A1 (en) | Dual-Lumen Drug Reservoir Fill and Withdrawal Devices and Methods | |
| CN200960185Y (en) | Controllable degradable anti-cancer medicine sustained-release film support |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |